No Data
Express News | Market news: Viking Therapeutics has achieved multiple endpoints in the Nash/Mash Phase 2B clinical trial results.
Viking Therapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024
Viking Therapeutics to Present Data From Phase 2b VOYAGE Study of VK2809 in Patients With Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
Peace Medical Acquired by Experienced Healthcare Professional, Ensuring Continuity and Growth
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
No Data
No Data
